Get the Stockscreener App
0.5412
0.02%
0.000100
Century Therapeutics Inc stock is traded at $0.5412, with a volume of 1.03M.
It is up +0.02% in the last 24 hours and down -5.93% over the past month.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
See More
Previous Close:
$0.5411
Open:
$0.541
24h Volume:
1.03M
Relative Volume:
1.09
Market Cap:
$46.63M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-0.2363
EPS:
-2.29
Net Cash Flow:
$-102.08M
1W Performance:
-3.67%
1M Performance:
-5.93%
6M Performance:
-25.87%
1Y Performance:
-69.07%
1-Day Range:
$0.5379
$0.5678
1-Week Range:
$0.5251
$0.5875
52-Week Range:
$0.3418
$2.05
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.5412 | 49.49M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Layoff Tracker: Opthea Slashes 80% of Workforce, 50% of Board - BioSpace
Using Bollinger Bands to evaluate Century Therapeutics Inc.Weekly Gains Summary & AI Optimized Trade Strategies - Newser
What earnings revisions data tells us about Century Therapeutics Inc.Recession Risk & AI Based Buy and Sell Signals - Newser
Is a relief rally coming for Century Therapeutics Inc. holdersQuarterly Investment Review & Stepwise Entry/Exit Trade Alerts - Newser
Published on: 2025-08-20 01:58:04 - Newser
What data driven models say about Century Therapeutics Inc.’s futureJuly 2025 Reactions & Verified Swing Trading Watchlist - Newser
Should you wait for a breakout in Century Therapeutics Inc.Weekly Trend Summary & Community Supported Trade Ideas - Newser
Is it too late to sell Century Therapeutics Inc.Quarterly Trade Review & Capital Efficient Trading Techniques - Newser
Reversal indicators forming on Century Therapeutics Inc. stockJuly 2025 WrapUp & Verified Chart Pattern Trade Signals - Newser
Understanding Century Therapeutics Inc.’s price movement2025 Analyst Calls & Detailed Earnings Play Strategies - Newser
Published on: 2025-08-19 13:48:58 - Newser
Published on: 2025-08-19 05:20:39 - Newser
What makes Century Therapeutics Inc. stock price move sharply2025 Risk Factors & Smart Money Movement Alerts - Newser
Technical analysis overview for Century Therapeutics Inc. stockMarket Growth Summary & Stock Portfolio Risk Management - Newser
Published on: 2025-08-18 15:55:24 - classian.co.kr
Century Therapeutics Q2 2025 Earnings Miss: Deep Losses and Market Caution - AInvest
Backtesting results for Century Therapeutics Inc. trading strategiesWeekly Trade Analysis & Consistent Income Trade Recommendations - Newser
Century Therapeutics Q2 Earnings Miss Spells Short-Term Volatility, but Sector Resilience Remains - AInvest
Measuring Century Therapeutics Inc.’s beta against major indicesJuly 2025 Market Mood & Low Drawdown Momentum Ideas - Newser
Is Century Therapeutics Inc. showing insider buyingDividend Hike & AI Forecasted Stock Moves - mustnews.co.kr
How hedge fund analytics apply to Century Therapeutics Inc. stock2025 Market Overview & Fast Moving Stock Watchlists - Newser
IPSC long term stock - AInvest
Century Therapeutics to Present Preclinical Data at EULAR 2025 Congress - MSN
Century Therapeutics (NASDAQ:IPSC) Lowered to “Sell” Rating by Wall Street Zen - Defense World
What institutions are buying Century Therapeutics Inc. stock nowWeekly Stock Analysis & Weekly Setup with High ROI Potential - Newser
Century Therapeutics 2025 Q1 Earnings Record Net Income Surges 372.8% - AInvest
Century Therapeutics Reports Q2 2025 Financials and Updates - TipRanks
Can Century Therapeutics Inc. expand its profit marginsJuly 2025 Review & Smart Swing Trading Alerts - newsyoung.net
Century Therapeutics shares fall 1.82% after-hours as patient dosing continues in CALiPSO-1 trial. - AInvest
Century Reports Flat Loss in Fiscal Q2 - AOL.com
Century Therapeutics (IPSC): Assessing the Value of Persistent Earnings Losses Amid Promising Pipeline Catalysts - AInvest
Century Therapeutics Reports Q2 Results and Leadership Change - TipRanks
Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Century Therapeutics pushes novel cell therapy into clinical trials, extends cash runway to 2027 - Stock Titan
Earnings visualization tools for Century Therapeutics Inc.July 2025 Fed Impact & AI Optimized Trading Strategy Guides - Newser
Century Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern Forming2025 Fundamental Recap & Real-Time Market Sentiment Alerts - Newser
Century Therapeutics Inc. Recovery Likely Here’s What Data ShowsExit Ready Momentum Stock Watchlist Expanded - 선데이타임즈
Century Therapeutics shares rise 1.35% after-hours following positive updates on FT819 and FT836 CAR T-cell products. - AInvest
Philly’s biotech industry keeps losing local jobs in a volatile market - WHYY
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Century Therapeutics Inc Stock (IPSC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Carr Douglas | SVP Finance & Operations |
Aug 04 '25 |
Sale |
0.53 |
296 |
158 |
405,686 |
| Carr Douglas | SVP Finance & Operations |
Jun 09 '25 |
Sale |
0.62 |
4,904 |
3,050 |
405,982 |
| Farid Adrienne | Chief Operations Officer |
Jun 09 '25 |
Sale |
0.62 |
552 |
343 |
250,141 |
| Pfeiffenberger Brent | President and CEO |
Jun 09 '25 |
Sale |
0.62 |
475 |
295 |
1,681,783 |
| Russotti Gregory | See Remarks |
Jun 09 '25 |
Sale |
0.62 |
526 |
327 |
392,047 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):